Apr 26, 2023Ymmunobio to Present at the Annual Meeting of the Association for Cancer Immunotherapy (CIMT)Presentation to focus on mechanism of action of anti-tumor activity for lead asset YB-200 RIEHEN, SWITZERLAND, April 26, 2023 ─...
Apr 11, 2023Ymmunobio Appoints New Chief Operating OfficerMartin E. Zuzulo to guide drug development operations for preclinical-stage biotech company RIEHEN, SWITZERLAND, April 11, 2023 –...
Mar 8, 2023Ymmunobio Accepted into Innosuisse Core CoachingParticipation in the international program guides startups in creating and developing business traction RIEHEN, SWITZERLAND, March 8,...
Mar 2, 2023Ymmunobio Welcomes Dr. Kanda and Dr. Khairnar to Advisory BoardMitsuro Kanda, MD, PhD, and Vishal Khairnar, PhD, join growing biotech company developing antibodies as therapies against various cancers...
Feb 28, 2023FDA Grants Orphan Drug Designation to Ymmunobio’s CEACAM Antibody for the Treatment of Liver CancerYmmunobio developed CEACAM antibody YB-200 for the treatment of hepatocellular carcinoma (HCC) RIEHEN, SWITZERLAND, February 28, 2023 ─...
Feb 16, 2023Ymmunobio Appoints Dr. Caroline Germa to Board of DirectorsMedical oncologist & CMO at Transcenta joins the board of growing biotech company February 16, 2023 ─ Ymmunobio, a preclinical stage...